期刊文献+

伴浆细胞分化的弥漫大B细胞淋巴瘤一例病例报告并文献复习 被引量:2

Diffuse large B cell lymphoma with plasma cell differentiation:a case report and literature review
下载PDF
导出
摘要 老年男性患者,以"腹股沟包块进行性肿大半年,肋骨疼痛2个月"为主诉入院,查体示脾大。既往贫血史30余年。入院化验示血清Ig M明显升高,血清免疫固定电泳示单克隆Ig M-κ阳性,外周血MYD88L265p突变阴性,骨髓涂片可见大量淋巴样浆细胞,骨髓免疫组化不除外脾边缘区淋巴瘤(SMZL)。后经淋巴结活检确诊为弥漫大B细胞淋巴瘤(DLBCL),经予CHOP方案化疗(环磷酰胺、吡柔比星、长春地辛、地塞米松)后取得部分缓解(PR)。 An elderly male patient admitted to our hospital with inguinal mass progressive enlargement for half a year, rib pain for 2 months, and more than 30 years of previous history of anemia. Physical examination revealed as splenomegaly. The serum level of IgM increased significantly, immunoelectrophoresis showed monoclonal IgM-κ positive,and the MYD88 L265 P mutation in peripheral blood was negative. A large number of lymphoid-plasma cells were seen in the bone marrow smear. Splenic marginal zone lymphoma( SMZL) could not be excluded by bone marrow immunohistochemistry.Eventually,he was diagnosed with nonGCB DLBCL based on lymph node biopsy, and partial response( PR) was achieved after CHOP regimen.
作者 杨融辉 廖爱军 YANG Rong-hui;LIAO Ai-jun(Department of Hematology,Shengjing Hospital of China Medical University,Shenyang 110004,China)
出处 《实用药物与临床》 CAS 2018年第6期680-682,共3页 Practical Pharmacy and Clinical Remedies
基金 国家自然科学基金(81272629) 沈阳市科技计划项目(17-231-1-58)
关键词 弥漫大B细胞淋巴瘤(DLBCL) 脾边缘区淋巴瘤(SMZL) 浆细胞分化 Diffuse large B cell lymphoma (DLBCL) Splenic marginal zone lymphoma (SMZL) Plasma cell differentiation
  • 相关文献

参考文献3

二级参考文献21

  • 1Korl AD, le Gessie S, Snijder S, et al. Primary extranodal non- Hodgkin' s lymphoma (NHL): the impact of alternative defini- tions tested in the Comprehensive Cancer Centre West popula- tion-based NHL registry. Ann Oncol, 2003, 14:131-139.
  • 2Li XQ, Li GD, Gao ZF, et al. The relative frequencies of lympho- ma subtypes in China: a nationwide study of 10002 cases by the Chinese Lymphoma Study Group. Ann Oncol, 2011, 22 Suppl 4: ivl41.
  • 3Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a stan- dard regimen (CHOP) with three intensive chemotherapy regi- mens for advanced non-Hodgkin' s lymphoma. N Engl J Med, 1993, 328:1002-1006.
  • 4Reyes F, Lepage E, Ganem G, et al. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med, 2005, 352:1197-1205.
  • 5Coiffier B, Thieblemont C, Van Den Neste E,et ah Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemother- apy in DLBCL patients: a study by the Grouped' Etudes des Lymphomes de 1' Adulte. Blood, 2010, 116:2040-2045.
  • 6Seki R, Ohshima K, Nagafuji K, et al. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Japan: a retrospective analysis of 1,057 cases from Kyushu Lymphoma Study Group. Int J Hematol, 2010, 9 I: 258-266.
  • 7Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol, 2005, 23:5027-5033.
  • 8Habermama TM, Weller EA, Morrison VA, et al. Rituximab- CHOP versus CHOP alone or with maintenance rituximab in old- er patients with diffuse large B-cell lymphoma. J Clin Oncol, 2006, 24:3121-3127.
  • 9Tilly H, Dreyling M. ESMO Guidelines Working Group. Diffuse large B-cell non-Hodgkin' s lymphoma: ESMO clinical recom- mendations for diagnosis, treatment and follow-up. Ann Oncol, 2008, Suppl 2:ii67-69.
  • 10NCCN Guidelines. Non-Hodgkin' s Lymphomas, version 2.2012.

共引文献273

同被引文献15

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部